SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : dsco Discovery Laboratories
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Arthur Radley who wrote (234)4/22/2009 11:55:43 AM
From: kenhott1 Recommendation  Read Replies (1) of 318
 
OT- I will just throw in a couple of comments about AMLN and people can as usual make up their own thoughts about my comments and what the comments would mean for the different companies. I do not believe Lirg is approvable. I think the thyroid problem is going to substantially overhang FDA decisions with all longer acting GLP-1 drugs. That includes Novo's drug, AMLN's LAR, Lilly's 2 long acting versions, etc. It is possible that AMLN's BID drug will be the only GLP-1 drug for a long time.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News